Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ChemoCentryx, Inc. stock logo
CCXI
ChemoCentryx
$51.99
$51.95
$14.95
$52.00
$3.71B1.221.68 million shs113 shs
Parker-Hannifin Co. stock logo
PH
Parker-Hannifin
$556.28
-11.6%
$654.89
$492.71
$718.44
$71.60B1.5682,888 shs1.79 million shs
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
$0.71
-10.0%
$0.87
$0.63
$6.80
$39.06M1.43258,870 shs154,610 shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ChemoCentryx, Inc. stock logo
CCXI
ChemoCentryx
0.00%0.00%0.00%0.00%0.00%
Parker-Hannifin Co. stock logo
PH
Parker-Hannifin
+3.37%-1.06%-2.91%+0.09%+15.10%
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
+2.19%+23.10%+15.09%-37.02%-82.96%
Remove Ads
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
ChemoCentryx, Inc. stock logo
CCXI
ChemoCentryx
N/AN/AN/AN/AN/AN/AN/AN/A
Parker-Hannifin Co. stock logo
PH
Parker-Hannifin
4.821 of 5 stars
4.43.04.21.54.21.71.3
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
2.6908 of 5 stars
3.21.00.00.02.85.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ChemoCentryx, Inc. stock logo
CCXI
ChemoCentryx
0.00
N/AN/AN/A
Parker-Hannifin Co. stock logo
PH
Parker-Hannifin
2.82
Moderate Buy$736.6532.42% Upside
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
2.33
Hold$4.00464.89% Upside

Current Analyst Ratings Breakdown

Latest PRLD, CCXI, and PH Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/3/2025
Parker-Hannifin Co. stock logo
PH
Parker-Hannifin
Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Peer Perform
3/10/2025
Parker-Hannifin Co. stock logo
PH
Parker-Hannifin
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$791.00 ➝ $750.00
2/19/2025
Parker-Hannifin Co. stock logo
PH
Parker-Hannifin
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$777.00 ➝ $824.00
2/7/2025
Parker-Hannifin Co. stock logo
PH
Parker-Hannifin
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$795.00
1/31/2025
Parker-Hannifin Co. stock logo
PH
Parker-Hannifin
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$842.00 ➝ $805.00
1/31/2025
Parker-Hannifin Co. stock logo
PH
Parker-Hannifin
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetHold ➝ Hold$689.00 ➝ $691.00
1/31/2025
Parker-Hannifin Co. stock logo
PH
Parker-Hannifin
KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$775.00 ➝ $790.00
1/31/2025
Parker-Hannifin Co. stock logo
PH
Parker-Hannifin
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$710.00 ➝ $775.00
1/31/2025
Parker-Hannifin Co. stock logo
PH
Parker-Hannifin
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$800.00 ➝ $791.00
1/24/2025
Parker-Hannifin Co. stock logo
PH
Parker-Hannifin
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetHold ➝ Hold$691.00 ➝ $689.00
(Data available from 4/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ChemoCentryx, Inc. stock logo
CCXI
ChemoCentryx
$32.22M115.14N/AN/A$4.09 per share12.71
Parker-Hannifin Co. stock logo
PH
Parker-Hannifin
$19.91B3.60$26.39 per share21.08$101.98 per share5.45
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
$7M5.58N/AN/A$4.32 per share0.16
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ChemoCentryx, Inc. stock logo
CCXI
ChemoCentryx
-$131.76M-$1.89N/AN/AN/A-357.01%-48.52%-30.59%N/A
Parker-Hannifin Co. stock logo
PH
Parker-Hannifin
$2.84B$24.1623.0218.992.8515.87%27.34%11.64%5/1/2025 (Estimated)
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
-$121.83M-$1.69N/AN/AN/AN/A-66.89%-55.59%5/6/2025 (Estimated)

Latest PRLD, CCXI, and PH Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/1/2025N/A
Parker-Hannifin Co. stock logo
PH
Parker-Hannifin
$6.73N/AN/AN/A$4.99 billionN/A
3/10/2025Q4 2024
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
-$0.49-$0.38+$0.11-$0.38N/A$4.00 million
1/30/2025Q2 2025
Parker-Hannifin Co. stock logo
PH
Parker-Hannifin
$6.23$6.53+$0.30$7.25$4.81 billionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
ChemoCentryx, Inc. stock logo
CCXI
ChemoCentryx
N/AN/AN/AN/AN/A
Parker-Hannifin Co. stock logo
PH
Parker-Hannifin
$6.521.17%+17.07%26.99%69 Years
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
N/AN/AN/AN/AN/A

Latest PRLD, CCXI, and PH Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
1/23/2025
Parker-Hannifin Co. stock logo
PH
Parker-Hannifin
quarterly$1.630.96%2/7/20252/7/20253/7/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ChemoCentryx, Inc. stock logo
CCXI
ChemoCentryx
0.02
4.54
4.47
Parker-Hannifin Co. stock logo
PH
Parker-Hannifin
0.51
1.06
0.59
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
N/A
7.04
7.04

Institutional Ownership

CompanyInstitutional Ownership
ChemoCentryx, Inc. stock logo
CCXI
ChemoCentryx
81.09%
Parker-Hannifin Co. stock logo
PH
Parker-Hannifin
82.44%
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
79.72%

Insider Ownership

CompanyInsider Ownership
ChemoCentryx, Inc. stock logo
CCXI
ChemoCentryx
8.30%
Parker-Hannifin Co. stock logo
PH
Parker-Hannifin
0.39%
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
62.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
ChemoCentryx, Inc. stock logo
CCXI
ChemoCentryx
17871.36 million65.43 millionOptionable
Parker-Hannifin Co. stock logo
PH
Parker-Hannifin
55,100128.72 million128.22 millionOptionable
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
12055.16 million20.47 millionOptionable

Recent News About These Companies

Prelude Therapeutics Founder Acquires 28% More Stock
Prelude Therapeutics CEO buys $467K in common stock
Barclays Sticks to Their Sell Rating for Prelude Therapeutics (PRLD)
Prelude Therapeutics reports FY24 EPS ($1.68), consensus ($1.77)
Prelude Therapeutics sees cash runway into 2Q26
Krishna Vaddi Bought 4.9% More Shares In Prelude Therapeutics

New MarketBeat Followers Over Time

Media Sentiment Over Time

ChemoCentryx stock logo

ChemoCentryx NASDAQ:CCXI

ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis. The company also develops TAVNEOS for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy, and lupus nephritis. In addition, it develops CCX559, an orally administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally administered inhibitor of the chemokine receptor known as CCR9, which has completed Phase I clinical trial for the treatment of inflammatory bowel disease. Further, the company has early-stage drug candidates that targets Th17 driven diseases and CCR6. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in San Carlos, California.

Parker-Hannifin stock logo

Parker-Hannifin NYSE:PH

$556.28 -72.70 (-11.56%)
Closing price 03:59 PM Eastern
Extended Trading
$554.02 -2.27 (-0.41%)
As of 07:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Parker-Hannifin Corporation manufactures and sells motion and control technologies and systems for various mobile, industrial, and aerospace markets worldwide. The company operates through two segments: Diversified Industrial and Aerospace Systems. The Diversified Industrial segment offers sealing, shielding, thermal products and systems, adhesives, coatings, and noise vibration and harshness solutions; filters, systems, and diagnostics solutions to ensure purity and remove contaminants from fuel, air, oil, water, and other liquids and gases; connectors used in fluid and gas handling; and hydraulic, pneumatic, and electromechanical components and systems for builders and users of mobile and industrial machinery and equipment. This segment sells its products to original equipment manufacturers (OEMs) and distributors who serve the replacement markets in manufacturing, packaging, processing, transportation, construction, refrigeration and air conditioning, agricultural, and military machinery and equipment industries. The Aerospace Systems segment offers products for use in commercial and military airframe and engine programs, such as control actuation systems and components, engine build-up ducting, engine exhaust nozzles and assemblies, engine systems and components, fluid conveyance systems and components, fuel systems and components, fuel tank inerting systems, hydraulic systems and components, lubrication components, avionics, sensors, pneumatic control components, thermal management products, fire detection and suppression systems and components, and wheels and brakes, as well as fluid metering, delivery, and atomization devices. This segment markets its products directly to OEMs and end users. The company markets its products through direct-sales employees, independent distributors, and sales representatives. Parker-Hannifin Corporation was founded in 1917 and is headquartered in Cleveland, Ohio.

Prelude Therapeutics stock logo

Prelude Therapeutics NASDAQ:PRLD

$0.71 -0.08 (-10.05%)
Closing price 04:00 PM Eastern
Extended Trading
$0.73 +0.02 (+3.52%)
As of 05:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.